Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics (NASDAQ:ARCT) in the last three months. The table below summarizes ...

The Arcturus subvariant stems from the Omicron strain of Covid-19 and is known as XBB.1.16 since it descends from the recombinant variant XBB, which combines two sublineages of Omicron BA.2.

Neda Safarzadeh, Sr. Director, Head of IR, PR & Marketing, Arcturus Therapeutics Holdings Inc., San Diego, CA, USA, Tel: +1-858-900-2682 Arcturus Therapeutics, based ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism (35% comfortable with technology) and challenges translating ...

São Paulo's Municipal Health Secretariat reported this week the first case of variant XBB.1.16 of Covid-19, also known as Arcturus in a 75-year-old man, bedridden and with comorbidities ...

Publications of the Astronomical Society of the Pacific Vol. 111, No. 759, May 1999 Adaptive Optics Observations of Arcturus... Adaptive Optics Observations of Arcturus using the Mount Wilson 100 Inch ...

Fintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy recommendation. As of December 23, 2024, the average one-year price ...

BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a price target of $63.00. Discover outperforming stocks ...

SAN DIEGO, February 04, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the ...